Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats
- 1 January 2022
- journal article
- research article
- Published by SERDI in The Journal Of Prevention of Alzheimer's Disease
- Vol. 9 (3), 480-490
- https://doi.org/10.14283/jpad.2022.18
Abstract
BACKGROUND: Alzheimer's disease (AD) is a continuum of events beginning with an increase in brain soluble A beta 342 followed by the appearance of hyperphosphorylated tau (P-tau, asymptomatic stage). Mild Cognitive Impairment (MCI) then appears (prodromal stage). However, the individual contribution of these two soluble proteins in the onset of the first cognitive symptoms remains unclear. OBJECTIVES: We sought to understand the specific impact of p-tau on the development of MCI in the AAV-AD rat model, a model of late-onset Alzheimer's disease (LOAD) predementia. METHODS: We specifically reduced the phosphorylation level of tau while leaving A beta 342 levels unchanged using a DYRK1A protein kinase inhibitor, Leucettine L41, in an adeno-associated virus-based Alzheimer's disease (AAV-AD) rat model. Leucettine L41 was administered by intraperitoneal injection at 20 mg/kg per day in AAV-AD rats from 9 (late asymptomatic phase) to 10 (prodromal phase) months of age. RESULTS: Decreased soluble forms of P-tau induced by chronic administration of Leucettine L41 did not change soluble A beta 342 levels but prevented MCI onset in 10-month-old AAV-AD rats. CONCLUSIONS: The present study argues that P-tau is required to induce the development of MCI. Consistent with our previous findings that soluble A beta 342 is also required for MCI onset, the data obtained in the AAV-AD rat model confirm that the transition from the asymptomatic to the prodromal stage may be caused by the combined presence of both soluble brain forms of A beta 342 and p-tau, suggesting that the development of MCI may be the consequence of their synergistic action.Keywords
This publication has 26 references indexed in Scilit:
- The Role of Amyloid-β Oligomers in Toxicity, Propagation, and ImmunotherapyEBioMedicine, 2016
- Suspected non-Alzheimer disease pathophysiology — concept and controversyNature Reviews Neurology, 2016
- Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementiaNeurology, 2015
- Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer's disease brainseLife, 2015
- Mild cognitive impairment: a concept in evolutionJournal of Internal Medicine, 2014
- Prefibrillar Tau Oligomers in Mild Cognitive Impairment and Alzheimer's DiseaseNeurodegenerative Diseases, 2013
- Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine BJournal of Medicinal Chemistry, 2012
- Leucettines, a Class of Potent Inhibitors of cdc2-Like Kinases and Dual Specificity, Tyrosine Phosphorylation Regulated Kinases Derived from the Marine Sponge Leucettamine B: Modulation of Alternative Pre-RNA SplicingJournal of Medicinal Chemistry, 2011
- DYRK1A-mediated Hyperphosphorylation of TauJournal of Biological Chemistry, 2007
- Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of TauopathyJournal of Neuroscience, 2007